GlobeNewswire
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
📈
AI Sentiment
Highly Positive
8/10
- Home
- ENTX
ENTX
Entera Bio Ltd.
as of 02-17-2026 2:36pm EST
$1.42
$0.08
-5.33%
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
| Founded: | 2010 | Country: | N/A |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 74.7M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 209.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $3.22 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -76.33% | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered ENTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 69.62%
69.62%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Entera Bio Ltd. (ENTX)
Taitel Haya
Buy
Director
ENTX Feb 10, 2026
Avg Cost/Share
$1.48
Shares
7,500
Total Value
$11,100.00
Owned After
0
SEC Form 4
Germano Geno J
Buy
Director
ENTX Feb 10, 2026
Avg Cost/Share
$1.49
Shares
20,000
Total Value
$29,800.00
Owned After
0
SEC Form 4
Ellis Sean
Buy
Director
ENTX Feb 9, 2026
Avg Cost/Share
$1.24
Shares
18,000
Total Value
$22,320.00
Owned After
178,098
SEC Form 4
Toledano Miranda Jayne
Buy
Chief Executive Officer
ENTX Dec 29, 2025
Avg Cost/Share
$1.81
Shares
11,000
Total Value
$19,912.20
Owned After
426,575
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Taitel Haya | ENTX | Director | Feb 10, 2026 | Buy | $1.48 | 7,500 | $11,100.00 | 0 | |
| Germano Geno J | ENTX | Director | Feb 10, 2026 | Buy | $1.49 | 20,000 | $29,800.00 | 0 | |
| Ellis Sean | ENTX | Director | Feb 9, 2026 | Buy | $1.24 | 18,000 | $22,320.00 | 178,098 | |
| Toledano Miranda Jayne | ENTX | Chief Executive Officer | Dec 29, 2025 | Buy | $1.81 | 11,000 | $19,912.20 | 426,575 |
Latest Entera Bio Ltd. News
ENTX Breaking Stock News: Dive into ENTX Ticker-Specific Updates for Smart Investing
Compare ENTX vs Leading Stocks
See how ENTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENTX Entera Bio Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.